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Abstract
Hypoxia-inducible factor 1 (HIF-1) is a critical heterodimeric transcription factor for 
tumor malignancy. Recently, ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) has 
been reported to function as a deubiquitinating enzyme for the stabilization of its 
α subunit (HIF-1α). In the present study, we showed that UCHL1 inhibition can be 
an effective therapeutic strategy against HIF-1-dependent tumor malignancy. In 
2D monolayer culture, a UCHL1 inhibitor suppressed HIF activity and decreased 
the transcription of HIF downstream genes by inhibiting the UCHL1-mediated ac-
cumulation of HIF-1α. Phenotypically, UCHL1 inhibition remarkably blocked cell mi-
gration. In 3D spheroid culture models, ectopic expression of UCHL1 significantly 
upregulated malignancy-related factors such as solidity, volume, as well as viable 
cell number in an HIF-1α-dependent manner. Conversely, inhibition of the UCHL1-
HIF-1 pathway downregulated these malignancy-related factors and also abolished 
UCHL1-mediated cell proliferation and invasiveness. Finally, inhibition of UCHL1 
promoted HIF-1α degradation and lowered the expression of HIF-1 target genes in 
the 3D model, as also observed in 2D monolayer culture. Our research indicates that 
the UCHL1-HIF-1 pathway plays a crucial role in tumor malignancy, making it a prom-
ising therapeutic target for cancer chemotherapy.
K E Y W O R D S
hypoxia-inducible factor 1, molecular target, spheroid, tumor malignancy, ubiquitin carboxyl-
terminal hydrolase L1
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1  | INTRODUC TION
Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) is a 223-amino 
acid protein that belongs to the ubiquitin carboxyl-terminal hydro-
lase (UCH) family of deubiquitinating enzymes.1,2 UCHL1 catalyzes 
the release of a ubiquitin (Ub) moiety from C-terminal extended Ub, 
such as Ub precursors and C-terminal Ub thioesters, to generate a 
monomeric Ub pool via de novo synthesis and salvage pathways.3 
It is also reported that UCHL1 digests poly-Ub chains conjugated to 
β-catenin by SCFβ-Trcp E3 ligase complex.4,5 Conversely, homodimeric 
and membrane-associated farnesylated UCHL1 is able to catalyze 
the formation of Lys48-linked poly-Ub chains on α-synuclein by act-
ing as an E3 Ub ligase.6
Ubiquitin carboxyl-terminal hydrolase L1 was originally iden-
tified as a brain-specific protein, known as protein-gene-product 
(PGP) 9.5, by 2D polyacrylamide gel electrophoresis analysis.7 The 
distribution of this enzyme in normal tissue is known to be highly 
limited, particularly in the brain,8 and moderately expressed in the 
pancreas,9 testis10 and urinary bladder.11 Aberrant expression of 
UCHL1 has been reported in renal cancer,12 non-small cell lung can-
cer,13 gastric cancer14 and colorectal cancer.5 In colorectal tumor 
tissues, UCHL1 was shown to activate the β-catenin/TCF signaling 
pathway by releasing an Ub moiety conjugated to β-catenin, result-
ing in the promotion of tumor malignancy.15
Hypoxia-inducible factor (HIF) is known to have pivotal roles in 
tumor malignancy16 and is considered a promising molecular target 
for cancer chemotherapy.17-19 HIF is a heterodimeric protein com-
prising α and β subunits: HIF-1α, HIF-2α and HIF-3α, and HIF-1β.20,21 
The protein expression levels of HIF-1α and HIF-2α are oxygen-de-
pendent and are tightly regulated by the ubiquitin-proteasome path-
way.22 Briefly, under aerobic conditions, two proline residues in the 
oxygen-dependent degradation (ODD) domain (eg, Pro-402 and 
Pro-564 of human HIF-1α) are hydroxylated by a dioxygenase named 
prolyl-4-hydroxylase (PHD).23 The von-Hippel-Lindau tumor sup-
pressor-elongin B/C-cullin 2 (VHL-EloBC-Cul2) E3 ligase complex is 
recruited onto the hydroxylated Pro-residues, and conjugates Lys48-
linked poly-Ub chain on the ε-NH2 residue of HIF-1α and HIF-2α.
24 
Conversely, in hypoxic microenvironments such as those in solid 
tumors, α subunit escapes degradation and is translocated to the 
nucleus, forming a heterodimer with HIF-1β.25 HIF specifically trans-
activates a variety of genes under promoter containing hypoxia-re-
sponsive elements (HRE), including GLUT1 and CA9.20,26 Previously, 
we reported that UCHL1 functions as a deubiquitinating enzyme 
for the stabilization of HIF-1α while blockade of the UCHL1-HIF-1α 
pathway suppresses the formation of metastatic tumors in mouse 
models.27
Recently, 3D culture systems have been increasingly and widely 
applied in preclinical studies to provide more physiologically relevant 
information. Compared with 2D cell culture, 3D cultured cells exhibit 
more similarities with tumor tissues with regards to cell morphology, 
proliferation, stage of cell cycle, gene expression and drug sensi-
tivity.28 Among these, higher expression of HIF-1α is considered as 
a critical factor that contributes to these features of 3D culture.29 
Therefore, we consider it crucial to elucidate the significance of the 
UCHL1-HIF-1α pathway in a 3D culture system.
In the present study, we investigated the potential roles of 
UCHL1 in cancer therapeutic approaches using a 3D spheroid culture 
system. We revealed that depletion of UCHL1 by siRNA or blockade 
of its deubiquitinating activity with a specific inhibitor caused a re-
markable decrease in HIF-1α protein levels in 3D spheroid culture 
models. Resulting reduction in expression of HIF-1α target genes in 
the spheroids, which are closely related to tumor malignancy includ-
ing metastasis, cell proliferation and angiogenesis, was observed. 
These findings suggest that the UCHL1-HIF-1α pathway is a promis-
ing therapeutic target in anticancer chemotherapy.
2  | MATERIAL S AND METHODS
2.1 | Plasmids and purification of recombinant 
protein
To construct pGEX6p-2/UCHL1, DNA encoding human UCHL1 gene 
was digested between EcoRV and XhoI in pcDNA4/UCHL1. This 
DNA fragment was then inserted between the SmaI and XhoI sites 
of PGEX6p-2 (Invitrogen). E coli DH5α harboring pGEX6p-2/UCHL1 
plasmid was induced with isopropyl β-D-1-thiogalactopyranoside. 
E coli DH5α was treated with sonication and dissolved in lysis buffer 
(50 mmol/L Tris-HCl [pH 8.0], 0.1 mol/L NaCl, 1 mmol/L EDTA, 
1 mmol/L DTT, 1% Triton X-100) The fusion protein GST/UCHL1 was 
first purified with glutathione-Sepharose 4B beads (GE Healthcare 
UK) and eluted with 20 mmol/L of glutathione (GSH; pH 8.5).
2.2 | Cell culture and reagents
HeLa, MDA-MB-231 and MDA-MB-436 cells were purchased from 
the American Type Culture Collection. Cells were incubated in 
DMEM containing 10% FBS and cultured in a well-humidified incuba-
tor with 5% CO2 and 95% air. For ˂0.1% O2 hypoxic incubation, cells 
were kept in a Bactron Anaerobic Chamber, BACTRONEZ (Sheldon 
Manufacturing, Cornelius). For ˂1% O2 incubation, cells were kept 
in a multi-gas incubator, MCO-5M (Panasonic). Camptothecin (CPT) 
and LDN57444 were obtained from FUJIFILM Wako Pure Chemical 
and Sigma-Aldrich, respectively. For 2D culture, Falcon tissue cul-
ture plates from Corning are used.
2.3 | Transient transfection
In HeLa cells, Lipofectamine 2000 (Thermo Fisher Scientific) 
was used at a ratio of 3:1 (reagent : DNA) to transiently trans-
fect HeLa/5HRE-Luc cells with pcDNA4/UCHL1 plasmid. In 
MDA-MB-231 and MDA-MB-436 cells, Lipofectamine LTX 
Reagent (Thermo Fisher Scientific) was used at a ratio of 9:1 (rea-
gent : DNA) for transfection. Lipofectamine 3000 (Thermo Fisher 
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Scientific) was used at a ratio of 2:1 (reagent : DNA) and 1:10 (μL of 
reagent : pmol of siRNA) for the co-transfection in MDA-MB-231 
cells.
2.4 | Luciferase assay and western blotting
For luciferase assays, HeLa/5HRE-Luc or HeLa/ ODD-Luc cells 
were seeded in 96-well plates at a concentration of 1 × 105 cells/
mL and incubated under normoxic conditions. After a 24-hour incu-
bation, cells were treated with each reagent for 1 hour. Cells were 
then transferred to normoxic or hypoxic conditions for another 
24-hour incubation and harvested in 100 μL of passive lysis buffer 
(Promega). Luciferase assays were performed using 100 μL of lucif-
erase assay reagent (Promega) or dual luciferase assay kit (Promega) 
according to the manufacturer’s instructions. Western blotting 
analysis was performed using anti–HIF-1α (BD Biosciences), anti–
UCHL1 (R&D Systems), anti–α-tubulin (Sigma-Aldrich), anti–β-actin 
(Sigma-Aldrich) and anti–β-tubulin (Abcam) as primary antibodies. 
Alkaline-phosphatase conjugated goat anti–mouse IgG antibody 
(Promega) was used as the secondary antibody. 5-Bromo-4-chloro-
3-indolyl-phosphate 4-toluidine salt (BCIP) and nitroblue tetra-
zolium (NBT) (Nacalai Tesque) was used to detect the indicated 
proteins.
2.5 | Wound healing assay and transwell 
migration assay
In the wound healing assay, MDA-MB-231 and MDA-MB-436 cells 
were seeded at a concentration of 5 × 105 cells/mL into 24-well 
plates (Corning). A wound was stimulated perpendicularly in each 
well of cells by scratching the cells with 200-μL pipette tips. Cells 
were washed with PBS (−) to remove debris and then incubated 
under normoxia or hypoxia. After 8, 24 and 48 hours, the recovery of 
gaps was measured by microscopy. In the transwell migration assay, 
MDA-MB-231 and MDA-MB-436 cells were seeded at a concentra-
tion of 5 × 105 cells/mL in Chemotaxicell chambers (8.0 μm pore; 
Kurabo) inserted into 24-well plates (Corning). Cells were pre–incu-
bated with DMEM containing 10% FBS for 24 hours and transferred 
into serum-free medium with chemoattractant for another 24-
hour incubation period. Cells were immobilized with methanol and 
stained with crystal violet (Nacalai Tesque). The number of migrated 
cells was counted under the microscope.
2.6 | siRNA transfection
For the depletion of UCHL1 and HIF-1α in MDA-MB-436 cells, 
cells were plated in 6-well or 24-well tissue culture plates 
(Corning) at a concentration of 1.2 × 105 cells/mL and cultured 
in antibiotic-free DMEM medium containing 10% of FBS. For 
transfection of 6-well or 24-well cultures, 10 or 50 pmol of siRNA 
(siUCHL1: silencer Select Validated siRNA, Cat# 4390824-s14616; 
Thermo Fisher Scientific: 5′-AAGUUAGUCCUAAAGUGUATT-3′, 
4390824-s14617: 5′-GCACAAUCGGACUUAUUCATT-3′ siHIF-1α: 
silencer Select Validated siRNA, Cat# 4390824-s6539 and Cat# 
4390824-s6541) with Lipofectamine RNAiMAX or Lipofectamine 
3000 (Thermo Fisher Scientific) was used, respectively. After 48-
hour transfection, the cells were lysed and subjected to western 
blotting analysis or immunofluorescent staining. For the negative 
control, scrambled siRNA (Cat# 12935-300, sequence information 
not disclosed; Life Technologies) was used. For 3D culture, cells 
were first cultured and transfected with siRNA as indicated above, 
then collected after a 24-hour incubation and cultured on 3D cul-
ture 96-well plates (Corning).
2.7 | Immunofluorescent staining
For HIF-1α and UCHL1 staining in 2D culture, cells treated with 
each condition were washed with PBS (−) and fixed in 4% para-
formaldehyde at room temperature for 15 minutes, followed by 
permeabilization with 0.1% Triton X-100 for 10 minutes on ice. The 
coverslips were blocked with 3% BSA for 12 hours and incubated 
with anti–HIF-1α (1:500; BD Biosciences) and anti–UCHL1 (1:500; 
R&D Systems) antibodies for 1 hour at 4°C. After three 5-minute 
washes with PBS (–), samples were probed with goat anti–rabbit 
polyclonal secondary antibody (Alexa Fluor 488, 1:1000; Abcam) 
or goat anti–mouse polyclonal secondary antibody (Alexa Fluor 
568, 1:1000; Abcam) mixed with 4′,6-diamino-2-phenylindole 
(DAPI) (1:5000, Roche) at room temperature for 1 hour. The cover-
slips were mounted onto slides with Dako Fluorescence Mounting 
Medium (Agilent). Fluorescence was detected by fluorescence mi-
croscopy (Olympus).
2.8 | Quantitative RT-PCR analysis
For 2D culture, total RNA was extracted from cells untreated or 
treated with 3.7 μmol/L LDN57444 for 24 hours using the Total 
RNA Extraction Miniprep System (Viogene). Reverse transcrip-
tion was performed using ReverTra Ace qPCR RT Master Mix with 
gDNA Remover (TOYOBO). Quantitative real-time PCR (qRT-PCR) 
reactions were performed in duplicate in a 20-μL volume containing 
0.25 μmol/L of each primer, 2 μL of cDNA template and 1 × SYBR 
Green (Applied Biosystems). qRT-PCR was performed using the 
StepOnePlus Real-Time PCR System (Thermo Fisher Scientific) ac-
cording to the manufacturer’s instructions. The primers used for PCR 
were as follows: human GLUT1: 5′-TGACAAGACACCCGAGGAGC-3′ 
(forward), 5′-GTCCAGCCCTACAGATTAGC-3′ (reverse); 
human CA9: 5′-AACGTCCCACCCTGCTGCTTTT-3′ (for-
ward), 5′-TGTACAGCTTCAGTTTCCCCCGGA-3′ (reverse); and 
human HIF1α: 5′-TACTAGCTTTGCAGAATGCTC-3′ (forward), 
5′-GCCTTGTATAGGAGCATTAAC-3′ (reverse). The relative expression 
levels of HIF1α, GLUT1 and CA9 mRNA were normalized to 18S RNA.
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2.9 | 3D culture and cell viability analysis
In the 3D culture, cells were cultured at a concentration of 1 × 105 cells/
mL on ultra-low attachment (ULA) spheroid microplates (Corning) for 
specific time periods. The viability of cultured cells was measured using 
the CellTiter-Glo Luminescent Cell Viability Assay (Promega).
2.10 | Morphological analysis of 3D tumor cultures
To evaluate characteristics including equivalent diameter, spheroid 
area, volume, solidity and sphericity, images of spheroid cells were 
taken using an Olympus CKX53 inverted microscope. Photos were 
then processed with open source image processing suites writ-
ten in MATLAB (Te MathWorks), AnaSP and ReViSP to acquire 3D 
brightfield images and morphological 2D and 3D malignancy-related 
factors.
2.11 | Spheroid invasion assay
Five days after plating in ULA spheroid microplates, the culture 
medium was changed to DMEM, containing FBS (final concentra-
tion = 10%), penicillin-streptomycin (final concentration = 1%), col-
lagen I (final concentration = 0.5 mg/mL) and basement membrane 
extract (BME; final concentration = 5 mg/mL). Photo of cells was 
F I G U R E  1   Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) is involved in the regulation of hypoxia-inducible factor 1α (HIF-1α) 
protein expression. A, Scrambled siRNA (Scr) or UCHL1-siRNA (siUCHL1) transfected MDA-MB-436 cells were incubated under hypoxic 
conditions (1% O2) for 24 h before western blotting analysis using the indicated antibodies. B, MDA-MB-436 cells were treated with 3.7 or 
7.5 μmol/L of LDN57444 under normoxia (21% O2) for 24 h and then incubated under hypoxia (1% O2) for another 24 h. Cells were then 
lysed and subjected to western blotting analysis. C, MDA-MB-231 cells were transiently transfected with either pcDNA4/UCHL1 (UCHL1) 
or pcDNA4/myc-His A (empty vector (EV)) and treated with DMSO or LDN57444 (3.7 μmol/L) under normoxia (21% O2) for 24 h. Cells were 
then transferred to hypoxia (1% O2) for another 24 h incubation before western blotting analysis. D, E, Scr- or siUCHL1-transfected MDA-
MB-436 cells were incubated under hypoxic conditions (1% O2) for 24 h. Cells were then fixed and subjected to immunostaining
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taken after another 2-day incubation. The surface area of the in-
vaded cells was measured using ImageJ.30
2.12 | Spheroid viability staining and spheroid 
immunofluorescent staining
Five days after plating in ULA spheroid microplates, cells were 
stained with a mixture of 1 mmol/L of Calcein-AM, 1 mmol/L of 
EthD-1 and 20 μmol/L of Hoechst 33342 for 4 hours and then im-
aged. Images were acquired with a confocal fluorescence micro-
scope (Nikon) at room temperature. For 3D staining, spheroids were 
washed with PBS (−) and fixed in 4% paraformaldehyde at room tem-
perature for 20 minutes and then permeabilized with 0.3% Triton 
X-100/PBS (−) and protease inhibitors for 20 minutes on ice. Samples 
were blocked with 3% of BSA/1% Triton X-100/PBS (−) at room tem-
perature for 1 hour and incubated at 4°C with primary antibodies 
against HIF-1α (1:400; BD Biosciences) and anti–UCHL1 (1:400; R&D 
F I G U R E  2    Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) inhibition or deficiency lowers hypoxia-inducible factor (HIF-1) activity 
and blocks the metastatic potential of tumor cells. A, HeLa/5HRE-luciferase cells were transiently transfected with either empty vector (EV) 
or UCHL1. Cells were then transferred to normoxic (21% O2) or hypoxic (1% O2) conditions for 5HRE-luciferase assays. B, 5HRE-luciferase-
UCHL1 cells were treated with various concentrations of LDN57444 for 1 h and transferred to hypoxic conditions for another 24 h incubation 
before measuring luciferase activity. C, 5HRE-luciferase-UCHL1 cells were treated with DMSO, camptothecin (CPT; 0.25 μmol/L) or LDN57444 
(3.7 μmol/L) for 1 h and incubated under hypoxic conditions for 24 h to be subjected to western blotting analysis. D, HeLa/ODD-Luc cells were 
treated with LDN57444 (3.7 μmol/L) or DMSO for 1 h under normoxia and transferred to hypoxia for another 24-h incubation before obtaining 
luminescence measurements. Relative firefly luciferase activity was normalized using Renilla luciferase activity. E, F, MDA-MB-231 cells were 
transfected with the indicated plasmids and treated with LDN57444 (3.7 μmol/L) for 1 h under normoxia before being transferred to hypoxic 
conditions for a 4-h incubation. Immunostaining was then performed with the indicated antibodies. G, H, MDA-MB-231 or MDA-MB-436 cells 
were treated with LDN57444 (3.7 μmol/L) and maintained under normoxic or hypoxic conditions for another 24 h. RNA was then collected and 
subjected to RT-qPCR to quantify the mRNA levels of the indicated genes. I, J, Wound healing assays were conducted with MDA-MB-231 and 
MDA-MB-436 cells. Cells were treated with DMSO or LDN57444 (2.5 μmol/L) for 24 h and then scratched with a P200 tip. Recovery rate of 
scratched gaps were measured over time (middle) and after 48 h (right). K, L, Transwell migration assays were conducted with MDA-MB-231 
and MDA-MB-436 cells. Cells were pre–incubated with serum-free medium for 24 h and transferred into 10% FBS/DMEM medium with DMSO 
or LDN57444 (2.5 μmol/L) for 24 h before measuring the number of migrated cells. M, MDA-MB-231 and MDA-MB-436 cells were treated 
with LDN57444 (2.5 μmol/L) and cell number was measured after 8, 24 and 48 h. Data is shown as mean ± SD; n = 3. Error bar indicates SD of 
the mean of three independent tests. *P < 0.05, **P < 0.01 was verified with Tukey’s honestly significant difference test or Student’s t-test
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Systems) overnight. After three washes with 0.1% Triton X-100/PBS 
(−), samples were probed with goat anti–rabbit polyclonal second-
ary antibody (Alexa Fluor 488, 1:500; Abcam) or goat anti–mouse 
polyclonal secondary antibody (Alexa Fluor 568, 1:500; Abcam) 
mixed with DAPI (Roche) at room temperature for 1 hour. Images 
were acquired with a confocal fluorescence microscope (Nikon) at 
F I G U R E  2   (Continued)
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room temperature. Fluorescent intensity was quantified using cellS-
ens software (Olympus).
3  | RESULTS
3.1 | Ubiquitin carboxyl-terminal hydrolase L1 is 
involved in the regulation of hypoxia-inducible factor 
1α protein expression
Because UCHL1 has been reported to stabilize HIF-1α with its deubiq-
uitinating activity, we first tested whether knockdown of UCHL1 gene 
could lead to a decrease in the protein levels of HIF-1α. As expected, less 
HIF-1α accumulation was confirmed in human breast adenocarcinoma-
derived MDA-MB-436 cells, which have endogenous UCHL1 expres-
sion, when treated with siUCHL1 compared with the mock group under 
hypoxia (Figure 1A). Under normoxia, due to the oxygen-dependent 
degradation, the HIF-1α immunoblotting signal was too weak to detect 
(data not shown). We further tested whether a UCHL1 inhibitor could 
have the same effect. We found that the well-known UCHL1 inhibitor, 
LDN57444 with an IC50 of 3.7 μmol/L, lowered HIF-1α protein stability 
to the same extent as that of siUCHL1 (Figure 1B). We also examined 
whether the UCHL1 inhibitor could have the same inhibitory effect 
on HIF-1α accumulation in the case of ectopic UCHL1 expression. In 
F I G U R E  3   Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) deficiency or inhibition leads to UCHL1-dependent cell death in 3D culture. 
A, MDA-MB-231 cells were transiently transfected with either empty vector (EV) or UCHL1. MDA-MB-436 cells were transfected with 
either scrambled siRNA (Scr), or UCHL1-siRNA (siUCHL1), or treated with LDN57444 (15 μmol/L). Cells were seeded on ultra-low attachment 
(ULA) spheroid microplates and incubated for 6 d before imaging. B, Corresponding 3D reconstructions of cells were obtained using ReViSP. 
Malignancy-related factors including equivalent diameter, spheroid area, volume, solidity and sphericity were further analyzed with AnaSP. 
Spheroid cell number was measured with a CellTiter-Glo 3D cell viability assay. C, UCHL1- or mock-transfected MDA-MB-231 cells, and 
siUCHL1-transfected or Scr-transfected or LDN57444 (15 μmol/L)-treated MDA-MB-436 cells were seeded on ULA spheroid microplates. On 
the last day of incubation, cells were stained with Hoechst 33342 (blue), Calcein-AM (green) and EthD1 (red) for imaging by confocal fluorescence 
microscopy. D, UCHL1-transfected or mock-transfected MDA-MB-231 cells were seeded on ULA spheroid microplates for 6 d. Medium was 
replaced with a mixture of DMEM, FBS, Collagen I, basement membrane extract (BME), and DMSO or LDN57444 (15 μmol/L) for another 2-d 
incubation period. The surface area of the invaded cells was measured using ImageJ. Data is shown as mean ± SD; n = 3. Error bar indicates SD of 
the mean of three independent tests. *P < 0.05, **P < 0.01 was verified with Tukey’s honestly significant difference test or Student’s t-test
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MDA-MB-231 cells, a human breast cancer cell line with no endogenous 
UCHL1 protein expression, protein expression of HIF-1α was elevated 
by the overexpression of UCHL1, while LDN57444 treatment canceled 
this effect (Figure 1C). Because the translocation of HIF-1α into the nu-
cleus is necessary for its transactivation activity, we examined where 
silencing of UCHL1 would affect HIF-1α protein expression. Depletion 
of UCHL1 lowered HIF-1α protein expression not only in the nucleus 
but also in cytosol under both normoxia and hypoxia, indicating that the 
stabilization of HIF-1α by UCHL1 is before its translocation into the nu-
cleus (Figure 1D,E and S1). Taken together, UCHL1 was demonstrated 
to upregulate HIF-1α protein expression, and its knockdown or pharma-
cological inhibition could counteract this effect.
3.2 | Ubiquitin carboxyl-terminal hydrolase L1 
inhibition or deficiency lowers hypoxia-inducible 
factor 1 activity and blocks the metastatic potential of 
tumor cells
As HIF-1α is a critical factor in transactivation modulation, we con-
ducted 5HRE-luciferase (5HRE-Luc) gene reporter assays in which HeLa 
cells were stably transfected with the firefly luciferase gene driven by 
5HRE to measure HIF activity. The UCHL1-expressing group showed 
a significant increase in 5HRE-Luc activity under both normoxia and 
hypoxia (Figure 2A). To investigate whether the UCHL1 inhibitor could 
affect HIF-1 activity, we further stably transfected HeLa/5HRE-Luc 
cells with UCHL1 expressing vector and treated these cells with various 
concentrations of LDN57444. This resulted in a significant decrease in 
the reporter activity in a dose-dependent manner (IC50: 3.7 μmol/L; 
Figure 2B). Using the same cells, we also found that treatment of 
LDN57444 decreased the accumulation of 5HRE-luciferase protein 
expression compared with the DMSO-treated group under hypoxia. 
Camptothecin, a type I topoisomerase inhibitor that blocks global tran-
scription activation was used as a positive control (Figure 2C). We then 
performed ODD-luciferase (ODD-Luc) assays to further determine the 
effect of UCHL1 on HIF-1α stability. HeLa cells were stably transfected 
with a gene encoding luciferase N-terminally fused with the ODD 
domain of HIF-1α, which was driven by the SV40 promoter. Under 
normoxia, the ODD domain is hydroxylated and subsequently ubiquit-
inated by pVHL to be rapidly degraded with a fused luciferase protein. 
However, under hypoxia, because of the insufficient oxygen for hy-
droxylation, the ODD-luciferase protein escapes from ubiquitination to 
release luminescence. Thus, this ODD-luciferase assay exactly mimics 
the process by which HIF-1α is accumulated or degraded but in a highly 
quantitative manner. We found that under both normoxia and hypoxia, 
the overexpression of UCHL1 led to a significant increase in the ODD-
Luc activity while LDN57444 eliminated this effect (Figure 2D and S2). 
When confirming by immunostaining analysis, the protein expression 
of HIF-1α was significantly elevated in UCHL1-transfected cells, while 
treatment with LDN57444 abrogated this increase in both nucleus and 
cytosol (Figure 2E,F and S1). To identify whether inhibition of UCHL1 
could deactivate the downstream activity of the UCHL1-HIF-1α axis, we 
analyzed the effect of LDN57444 on the expression of two typical can-
cer-related HIF-1α target genes, GLUT1 and CA9, in both MDA-MB-231 
and MDA-MB-436 cells. In UCHL1-non-expressing MDA-MB-231 
cells, blockade of UCHL1 by LDN57444 had no significant influence 
on the expression of both genes. In UCHL1-expressing MDA-MB-436 
cells, however, LDN57444 lowered the expression of both genes re-
markably under normoxia, while this effect was further amplified under 
hypoxia, revealing the specificity of the UCHL1 inhibitor (Figure 2G,H). 
In conclusion, UCHL1 increased the stability of HIF-1α protein to pro-
mote HIF-1 activity while UCHL1 inhibition could eliminate this effect.
In murine models of pulmonary metastasis, UCHL1 has previously 
been shown to have an important role in the promotion of tumor cell 
metastasis.27 To evaluate whether UCHL1 inhibitor has an anti–me-
tastasis effect, we performed wound healing and transwell migration 
assays in cultured cells. Treatment with LDN57444 significantly sup-
pressed the recovery of the scratched gap in MDA-MD-436 cells (76% 
inhibition), but not in MDA-MB-231 cells (Figure 2I,J). In the transwell 
migration assay, a similar result was obtained. LDN57444 treatment 
led to a striking decrease in the number of migrated MDA-MB 436 
cells. Meanwhile, in MDA-MB-231 cells, no such effect was confirmed 
(Figure 2K,L). Finally, we examined whether this difference was possi-
bly induced by a potential inhibitory effect of LDN57444 on the pro-
liferation of MDA-MB-436 cells. We treated both MDA-MB-231 and 
MDA-MB-436 cells with 2.5 μmol/L of LDN57444 and found no dif-
ference in cell number between both cell lines after 8, 24 and 48 hours 
(Figure 2M). Overall, UCHL1 inhibition showed efficacy against UCHL1-
mediated cell migration in endogenous UCHL1-expressing cells.
3.3 | Ubiquitin carboxyl-terminal hydrolase L1 
deficiency or inhibition leads to ubiquitin carboxyl-
terminal hydrolase L1-dependent cell death in 3D culture
It has been demonstrated in many studies that anchorage-inde-
pendent cultured cells can form spheroids.28 Spheroids usually 
contain three areas: the proliferative area in the outer layer, the 
F I G U R E  4   Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) inhibition decreases viable cell number and invasiveness under 3D culture 
in a hypoxia-inducible factor 1α (HIF-1α)-dependent manner. A, MDA-MB-231 cells co-transfected with empty vector (EV)/UCHL1 and 
Scr/HIF-1α siRNA (siHIF-1α) for 48 h and were collected to be applied to western blotting analysis. B, MDA-MB-231 cells co-transfected 
with EV/UCHL1 and Scr/siHIF-1α were cultured in ULA spheroid microplates for 3 d to form spheroids. Medium was then replaced with a 
mixture of DMEM, FBS, collagen I, basement membrane extract (BME) and DMSO or LDN57444 (15 μmol/L) for another 2-d incubation 
period. Quantification data for malignancy-related factors are shown in Figure S4. C, D, MDA-MB-231 cells co-transfected with EV/UCHL1 
and scrambled/siHIF-1α for 24 h and were collected to be cultured in ULA spheroid microplates for another 5 d before their images were 
taken (C) or spheroid viability staining was performed (D). Data is shown as mean ± SD; n = 3. Error bar indicates SD of the mean of three 
independent tests. *P < 0.05, **P < 0.01 was verified with Tukey’s honestly significant difference test or Student’s t-test
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quiescent area in the intermediate layer and the necrotic core area 
in the central layer. Compared with traditional 2D monolayer cul-
tures, spheroids share more similarities with solid tumor tissues in 
features such as lower pH, cell-cell interactions, interstitial pres-
sure, and drug accessibility, as well as variations in O2 and nutrient 
accessibility.28,31 Among these, the specific property that makes 
them good models in the study of HIF-related malignancies is that 
they exhibit areas of varied oxygen conditions. Therefore, we per-
formed 3D spheroid cell culture to learn more about the link be-
tween UCHL1 and HIF1-dependent tumor malignancy.
We first compared typical malignancy-related factors, such 
as equivalent diameter, spheroid area, volume, solidity, sphericity 
and viable cell number when cells were incubated in an anchor-
age-independent condition.32 In UCHL1-transfected MDA-MB-231 
cells, all factors were evidently elevated (Figure 3A,B). However, 
these factors were drastically reduced in siUCHL1-transfected 
MDA-MB-436 cells. In the case of UCHL1 inhibitor treatment in 
MDA-MB-436 cells, LDN57444 abated the diameter, area, volume 
and viable cell number but had no significant effect on solidity and 
sphericity (Figure 3B).
The central part of a spheroid, which is named the necrotic area, 
has been reported to have a relatively lower cell viability. Thus, we 
first determined whether UCHL1 transfection could rescue these 
centrally located cells. Living and dead cells were stained with 
Calcein-AM and EthD1, respectively. Surprisingly, transfection of 
UCHL1 in MDA-MB-231 cells was confirmed to rescue cells not 
only in the central but also in the intermediate layer of the quiescent 
area. Moreover, more living cells were confirmed in the proliferative 
area of UCHL1-transfected cells, suggesting a proliferation-promot-
ing effect of UCHL1 under 3D culture conditions (Figure 3C and S3). 
When MDA-MB-436 cells were treated with LDN57444 or trans-
fected with siRNA against UCHL1, global cell death was dramatically 
increased compared with the control group. Therefore, we consider 
that the rescue of cell death and the increase in proliferation both 
contributed to the increase in total viable cell number (Figure 3C).
In 3D cultured models, metastasis in breast cancer cell is pro-
moted due to features such as low oxygen, low pH and low glucose 
environments.33 Therefore, we applied a 3D cell invasion assay to 
confirm whether UCHL1 could have a metastasis-promoting ef-
fect in spheroid models. Transfection of UCHL1 substantially pro-
moted cell invasion under 3D culture conditions, while treatment 
with LDN57444 eliminated this increase (Figure 3D). In conclusion, 
UCHL1 increases malignant potential in spheroid cultured tumor 
cells, while its deficiency or inhibition can abrogate this effect.
3.4 | Ubiquitin carboxyl-terminal hydrolase 
L1 inhibition decreases viable cell number and 
invasiveness under 3D culture in a hypoxia-inducible 
factor 1a-dependent manner
To examine whether the phenotypes observed in Figure 3 were induced 
in an HIF-1α-dependent manner, we performed a co-transfection of 
UCHL1 and siHIF-1α in MDA-MB-231 cells (Figure 4A). We first exam-
ined whether the overexpression of UCHL1 in HIF-1α deficient cells 
could still affect spheroid phenotypes due to its deubiquitinating activ-
ity against other potential substrates except for HIF-1α. We found that 
neither the transfection of UCHL1 nor the treatment of LDN57444 
showed any effect on the invasiveness in the siHIF-1α transfected 
groups (Figure 4B). We further examined other malignancy-related fac-
tors and found that the siHIF-1α-transfected spheroids were hollowed in 
the central part of the sphere, despite UCHL1-transfection, LDN57444-
treatment or their combination (Figure 4C). Because HIF-1α is mostly 
accumulated in the necrotic and quiescent layers of spheroids and is in-
dispensable for their viability,29 depletion of HIF-1α almost completely 
disassembled the spheroid. When quantified (Figure S4), siHIF-1α groups 
in general showed a drastically lower solidity, sphericity, volume and cell 
number compared with the scrambled-transfected group. When HIF-1α 
deficient cells were transfected with UCHL1 or further treated with 
LDN57444, no variation was found in these malignancy-related factors.
Finally, spheroid cells showed no difference in the number of live 
or dead between the empty vector (EV)-transfected and UCHL1-
transfected groups (Figure 4D) in siHIF-1α-transfected groups. 
These results demonstrate the dependency on HIF-1α for UCHL1 
to raise tumor cell malignancy, while the blockade of the UCHL1-
HIF-1α axis abrogated this effect.
3.5 | Ubiquitin carboxyl-terminal hydrolase L1 
inhibition reduces hypoxia-inducible factor 1α protein 
expression under 3D culture
To confirm whether the observed malignancy-promoting effect 
could be ascribed to the activation of the UCHL1-HIF-1α axis, we 
F I G U R E  5    Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) inhibition reduces hypoxia-inducible factor 1α (HIF-1α) protein expression 
under 3D culture. A, UCHL1-depleted or mock-transfected MDA-MB-436 cells were seeded on ULA spheroid microplates for 5 d before 
western blotting analysis. B, UCHL1-transfected or mock-transfected MDA-MB-231 cells were seeded on ULA spheroid microplates for 
5 d, treated with DMSO or LDN57444 (15 μmol/L) for 48 h and subjected to western blotting analysis. C, Scr or siUCHL1-transfected 
or LDN57444 (15 μmol/L)-treated MDA-MB-436 cells were seeded on ULA spheroid microplates for 5 d for 3D immunostaining. D, 
Quantification of results of C. E, UCHL1-transfected or mock-transfected MDA-MB-231 cells were seeded on ULA spheroid microplates 
for 5 d, treated with DMSO or LDN57444 (15 μmol/L) for 48 h, and subjected to 3D immunostaining with the indicated antibodies. 
F, Quantification of results of E. G, H, UCHL1-transfected or mock-transfected (G) or empty vector (EV)/UCHL1 and Scr/siHIF-1α-co-
transfected (H) MDA-MB-231 cells were seeded on ULA spheroid microplates for 5 d, treated with DMSO or LDN57444 (15 μmol/L) for 48 h, 
and subjected to RT-qPCR to quantify the mRNA levels of the indicated genes. Data is shown as mean ± SD; n = 3. Error bar indicates SD of 
the mean of three independent tests. *P < 0.05, **P < 0.01 was verified with Tukey’s honestly significant difference test or Student’s t-test
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investigated HIF-1α protein levels in scrambled-transfected or 
siUCHL1-transfected cells under 3D culture. We found that the ab-
sence of UCHL1 clearly decreased HIF-1α accumulation (Figure 5A). 
In MDA-MB-231 cells, as confirmed in 2D culture, overexpression of 
UCHL1 increased the protein expression of HIF-1α, while LDN57444 
treatment eliminated this effect (Figure 5B). Immunostaining of 3D 
cultures verified that silencing of the UCHL1 gene had a similar ef-
fect compared with that of LDN57444, which significantly sup-
pressed the protein expression of HIF-1α (Figure 5C,D). In addition, 
MDA-MB-231 cells with UCHL1 overexpression showed higher 
HIF-1α expression in all central, quiescent and proliferative areas. 
LDN57444 treatment once again remarkably decreased this effect 
(Figure 5E,F). The expression of two typical HIF-1α downstream 
genes, GLUT1 and CA9, was also elevated by UCHL1 overexpression 
in MDA-MB-231 cells, while this effect was abrogated by LDN57444 
(Figure 5G). Finally, UCHL1 failed to increase the expression of both 
genes in siHIF-1α-transfected groups (Figure 5H). Considering that 
GLUT1 and CA9 are both essential in tumor malignancy, we suppose 
this HIF-1α-dependent upregulation on both genes by UCHL1 is a 
critical cause of the phenotypes observed in Figure 4. In conclusion, 
UCHL1 was confirmed to increase cell viability and proliferation as 
well as metastasis potential by stabilizing HIF-1α to increase HIF-1 
activity in the spheroid 3D culture system.
4  | DISCUSSION
In the present study, we investigated the impact of pharmacologi-
cal inhibition of the deubiquitinating activity of UCHL1 on HIF-1-
dependent tumor malignancy in a 3D cell culture system. We clearly 
showed that LDN57444 (Figure S5), a well-known UCHL1 inhibitor, 
attenuated HIF-1α protein accumulation and lowered mRNA ex-
pression levels, causing cell death and reduced cell invasiveness in 
MDA-MB-436 as well as UCHL1-transfected MDA-MB-231 sphe-
roids in an HIF-1α-dependent manner. These results indicated that 
therapeutic strategies targeting UCHL1 are plausible for HIF-1α-
dependent tumors.
As shown in Figure 2, LDN57444 more effectively suppressed 
hypoxia-induced expression of GLUT1 and CA9 in MDA-MB-436 
cells cultured under hypoxic conditions than normoxia cultured 
cells. It has been reported that in Hep3B cells cultured in hy-
poxic conditions, HIF-1α is ubiquitinylated and the blockade of 
Ub-activating enzyme (E1 enzyme) by a specific inhibitor, UBE1-
41, resulted in an accumulation of HIF-1α protein. These find-
ings indicate that HIF-1α is also degraded via the Ub-proteasome 
pathway under hypoxia.34 While the pVHL E3 ligase-dependent 
degradation pathway is recognized as a dominant regulator of 
HIF-1α under normoxia, hypoxia-associated factor,35 receptor of 
activated protein kinase C 1 (RACK1)36 and parkin37 were iden-
tified as E3 ligases catalyzing the oxygen-independent ubiquiti-
nation of HIF-1α. UCHL1 contributes to the escape of a variety 
of proteins from their turnover in a hydrolase activity-dependent 
manner, including HIF-1α, by forming a UCHL1-HIF-1α complex, 
which is more abundantly detected in the nuclei of hypoxia-ex-
posed HeLa cells.27 Given that UCHL1 disassembles Lys48-linked 
poly-Ub chains conjugated to β-catenin5, epidermal growth fac-
tor receptor38 and NOXA,39 it is possible that UCHL1 stabilizes 
HIF-1α protein levels in hypoxic conditions through the removal of 
poly-Ub chains attached via an oxygen-independent mechanism 
or interference with Ub modification of HIF-1α by E3 ligases such 
as parkin. Furthermore, in Figure 5G, gene expression of GLUT1 
and CA9 were both downregulated in spheroids to a much greater 
degree. Because spheroids have a mixture of oxygen conditions, 
it is plausible that LDN57444 showed a much severer impact on 
HIF-1-dependent tumor malignancy in our 3D spheroid model. 
Therefore, blockade of the UCHL1-HIF-1α axis through UCHL1 in-
hibition can be a promising therapeutic strategy for the treatment 
of HIF-1-dependent tumors.
Ubiquitin carboxyl-terminal hydrolase L1 has been shown to 
promote tumor metastasis and cell proliferation via multiple signal 
transduction pathways. One is the stimulation of AKT through the 
inhibition of PH domain and leucine rich repeat protein phosphatase 
(PHLPP1), a negative regulator of AKT.40 Moreover, following the 
stabilization of both β-catenin (oxygen-independent) and HIF-1 (oxy-
gen-independent), subsequent activation of c-Jun N-terminal kinase 
(JNK) and p38 mitogen-activated protein (MAP) kinases41 promotes 
the expression of several genes controlling the metastasis, invasion 
and proliferation of cancer cells, such as matrix metalloproteinases 
(MMP), cyclin D1 and c-Myc.42 Because overexpression of UCHL1 
failed to increase the malignancy-related factors in HIF-1α deficient 
spheroid cells, we consider that UCHL1-HIF-1α axis is the dominant 
pathway rather than the other two in UCHL1-mediated tumors. In 
fact, as both AKT43 and Wnt/β-catenin44 signaling have been re-
ported to have crosstalk with HIF-1α, the central role of HIF-1α in 
UCHL1-mediated tumor malignancy is further confirmed.
Although the vital catalytic role of UCHL1 in the metastasis and 
aggravation of malignant tumors was confirmed in our research, the 
development of efficient UCHL1 inhibitors is still required, as only 
LDN57444 has been reported thus far.45 However, LDN57444 is not 
suitable for clinical application due to its side-effects, which include 
induction of endoplasmic reticulum stress and abnormal expression 
of synapse proteins.1,46,47 Therefore, the development of more ef-
fective and selective UCHL1 inhibitors remains a major challenge 
for the treatment of malignant tumors. The experiments we applied 
herein can be considered as an approach for the screening of po-
tent UCHL1 inhibitors. In particular, the 3D spheroid system using 
UCHL1-expressing tumor cells provides valuable information for the 
validation of UCHL1 inhibitor screening. We are now applying our 
in-house chemical library, which includes synthetic molecules as well 
as natural products, to identify novel UCHL1 inhibitors.
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